Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Common Equity (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Common Equity for 16 consecutive years, with $568.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 913.68% year-over-year to $568.4 million, compared with a TTM value of $568.4 million through Dec 2025, up 913.68%, and an annual FY2025 reading of $466.1 million, up 143.93% over the prior year.
  • Common Equity was $568.4 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $466.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $684.2 million in Q1 2025 and bottomed at $56.1 million in Q4 2024.
  • Average Common Equity over 5 years is $401.6 million, with a median of $427.6 million recorded in 2021.
  • The sharpest move saw Common Equity tumbled 67.72% in 2024, then surged 913.68% in 2025.
  • Year by year, Common Equity stood at $372.6 million in 2021, then increased by 6.39% to $396.4 million in 2022, then crashed by 56.17% to $173.7 million in 2023, then crashed by 67.72% to $56.1 million in 2024, then soared by 913.68% to $568.4 million in 2025.
  • Business Quant data shows Common Equity for ARWR at $568.4 million in Q4 2025, $466.1 million in Q3 2025, and $519.8 million in Q2 2025.